Financial Review: Palvella Therapeutics (PVLA) vs. The Competition

Palvella Therapeutics (NASDAQ:PVLA) is one of 1,068 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its rivals? We will compare Palvella Therapeutics to similar companies based on the strength of its earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability and risk.

Profitability

This table compares Palvella Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-80.93%	-59.55%
Palvella Therapeutics Competitors	-3,409.82%	-235.83%	-32.89%

Earnings & Valuation

This table compares Palvella Therapeutics and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Palvella Therapeutics	$42.81 million	-$24.54 million	-1.60
Palvella Therapeutics Competitors	$9.95 billion	$135.48 million	-7.62

Palvella Therapeutics’ rivals have higher revenue and earnings than Palvella Therapeutics. Palvella Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Palvella Therapeutics and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	0	0	4	0	3.00
Palvella Therapeutics Competitors	8184	21867	49741	1315	2.54

Palvella Therapeutics presently has a consensus price target of $40.33, indicating a potential upside of 108.23%. As a group, “Pharmaceutical preparations” companies have a potential upside of 199.93%. Given Palvella Therapeutics’ rivals higher possible upside, analysts plainly believe Palvella Therapeutics has less favorable growth aspects than its rivals.

Volatility and Risk

Palvella Therapeutics has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Comparatively, Palvella Therapeutics’ rivals have a beta of 3.64, meaning that their average share price is 264% more volatile than the S&P 500.

Insider and Institutional Ownership

40.1% of Palvella Therapeutics shares are held by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 6.4% of Palvella Therapeutics shares are held by insiders. Comparatively, 13.6% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Palvella Therapeutics rivals beat Palvella Therapeutics on 8 of the 13 factors compared.

About Palvella Therapeutics

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.